A Real World Study to Assess Overall Survival in Amyotrophic Lateral Sclerosis (ALS) Patients Treated with RADICAVA (Edaravone) Compared to a Control Group of Patients not Prescribed the Product

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 May 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 May 2021 New trial record
12 May 2021 According to a Mitsubishi Tanabe Pharma America media release, the company will be conducting further analysis of this real-world data with plans to submit the full results for publication in a peer-reviewed journal.
12 May 2021 According to a Mitsubishi Tanabe Pharma America media release, analysis is still ongoing, and the company looks forward to sharing more details about the methodology and findings with the ALS scientific community.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com